PIK3CA and cancer: While increasing evidence supports the compensatory activation of STAT3 kinase and its downstream signaling pathways is a common cause of resistance of different cancer cell types and oncogenic contexts to targeted therapies, whether it can play role in dampening the response to the PI3K inhibitors in PTEN-deficient cancer cells remains an unanswered question.